Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release

Drugs in R and D

Volumn 13, Issue 1, 2013, Pages 53-61

  Roesch, Benno ^a   Corcoran, Mary ^b   Haffey, Mary ^b   Stevenson, Annette ^b   Wang, Phillip ^b   Purkayastha, Jaideep ^b   Martin, Patrick ^b   Ermer, James ^b  

^a Advanced Biomedical Research Inc   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE; METHYLPHENIDATE;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG INTERACTION; DRUG RELEASE; DRUG SAFETY; FAINTNESS; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; VITAL SIGN;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GUANFACINE; HUMANS; MALE; METHYLPHENIDATE; YOUNG ADULT;

EID: 84876228940     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0009-5     Document Type: Article

References (21)

1. Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8(5):409-15.
2. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol. 1995;5(3):157-66.
3. Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol. 2004;14(1):129-36.
4. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501-10.
5. Intuniv (package insert). Wayne: Shire Pharmaceuticals Inc.; 2011.
6. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.
7. Pliszka SR, Crismon ML, Hughes CW, The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642-57.
8. McNeil Specialty Pharmaceuticals. Concerta (methylphenidate hydrochloride) extended-release tablets: briefing document. FDA PAC Mar 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b-14- McNeil%20FDA%20PAC%20March%2006%20Briefing%20Document.pdf. Accessed 26 Apr 2012.
9. Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Pharmacokinetics, pharmacodynamics, and drug disposition. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins; 2002.
10. Concerta (package insert). Titusville: McNeil Pediatrics; 2010.
11. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29(4):617-25.
12. Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003;42(4):393-401.
13. Biederman J, Melmed RD, Patel A, The SPD503 Study Group, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.
14. Sallee F, McGough J, Wigal T, The SPD503 Study Group, et al. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.
15. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047-55.
16. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-47.
17. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-35.
18. Meyer MC, Straughn AB, Jarvi EJ, et al. Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability. Pharm Res. 2000;17(4):381-4.
19. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.
20. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9(3):573-603. viii.
21. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23(1):93-102.